Sorry, I ran out of credit http://ecosistemapolitico.com/your-top-genericscom-review-97e6.pdf#exhibit your-top-generics.com review He said in a note to investors that ViroPharma could be a fit for larger companies seeking quality orphan assets, but believes the reward/risk profile of the shares is now better reflected in the higher valuation.